scholarly journals Therapeutic effect of hepatocyte growth factor-secreting mesenchymal stem cell in established rat liver fibrosis model

Cell Research ◽  
2008 ◽  
Vol 18 (S1) ◽  
pp. S155-S155
Author(s):  
Myung-Deok Kim ◽  
Sung-Soo Kim ◽  
Hyun-Young Cha ◽  
Seunghun Jang ◽  
Dayoung Chang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Growth Factor ◽  
Liver Fibrosis ◽  
Mesenchymal Stem Cell ◽  
Hepatocyte Growth Factor ◽  
Therapeutic Effect ◽  
Rat Liver ◽  
Rat Liver Fibrosis ◽  
Hepatocyte Growth

scholarly journals Treatment Efficiency of Different Routes of Bone Marrow-Derived Mesenchymal Stem Cell Injection in Rat Liver Fibrosis Model

2018 ◽  
Vol 48 (5) ◽  
pp. 2161-2171 ◽  
Author(s):  
Naglaa K. Idriss ◽  
Hayam G. Sayyed ◽  
Amany Osama ◽  
Dina Sabry
Keyword(s):  
Gene Expression ◽  
Bone Marrow ◽  
Stem Cell ◽  
Growth Factor ◽  
Liver Fibrosis ◽  
Mesenchymal Stem Cell ◽  
Rat Liver ◽  
Enzyme Linked Immunosorbent Assay ◽  
Rat Liver Fibrosis ◽  
Recovery Group

Background/Aims: The most appropriate route for bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation in the management of liver fibrosis remains controversial. This study investigated the therapeutic efficacy of intravenous and intrasplenic BM-MSC transplantation on carbon tetrachloride (CCl4)-induced rat liver fibrosis. Methods: Fifty rats were divided into 5 groups (n = 10 rats per group): healthy control group, CCl4 group, CCl4/ recovery group, CCl4/BM-MSC intravenous group, and CCl4/BM-MSC intrasplenic group. BM-MSCs were isolated, labeled with green fluorescent protein (GFP), and injected into fibrotic rats either intravenously or intrasplenically. Gene expression of interleukins (IL-1β and IL-6), interferon (INF)-γ, hepatic growth factor, and the hepatocyte-specific marker cytokeratin 18 was estimated by quantitative real-time reverse transcription-polymerase chain reaction. Vascular endothelial growth factor and connective tissue growth factor was detected by western blot analysis and enzyme-linked immunosorbent assay, respectively. At 2 weeks after intravenous and intrasplenic BM-MSC injections, GFP-positive cells were detected in liver tissue. Results: Both routes achieved a similar enhancement of liver function, which was confirmed by histopathological examination. The intravenous route was more effective than the intrasplenic route in reducing gene expression levels of IL-1β, IL-6, and INF-γ. However, fibrotic changes were still observed in the recovery group. Conclusion: Intravenous BM-MSC injection was an efficient and appropriate route for BM-MSC transplantation for the management of liver fibrosis.

scholarly journals Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models

2012 ◽  
Vol 15 (6) ◽  
pp. 862-870 ◽  
Author(s):  
Lianhua Bai ◽  
Donald P Lennon ◽  
Arnold I Caplan ◽  
Anne DeChant ◽  
Jordan Hecker ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cell ◽  
Growth Factor ◽  
Mesenchymal Stem Cell ◽  
Hepatocyte Growth Factor ◽  
Hepatocyte Growth

scholarly journals ID: 1041 Effectiveness of human adipose-derived stem cell therapy pretreated with hepatocyte growth factor in liver fibrosis mouse model

2017 ◽  
Vol 4 (S) ◽  
pp. 119
Author(s):  
Ngoc Hong Vo ◽  
Trinh Van Le ◽  
Nam Hai Nguyen ◽  
Yen K.T. Nguyen ◽  
Thanh Minh Dang ◽  
...  
Keyword(s):  
Growth Factor ◽  
Liver Fibrosis ◽  
Mouse Model ◽  
Hepatocyte Growth Factor ◽  
Therapeutic Effect ◽  
Smooth Muscle Actin ◽  
Alpha Smooth Muscle Actin ◽  
Promoting Effect ◽  
Significant Difference ◽  
Hepatocyte Growth

Background: Adipose-derived stem cells (ADSCs) have the potential therapeutic impact on the liver fibrosis. Hepatocyte growth factor (HGF) is pivotal for damage repair with its anti-apoptotic, anti-fibrotic and cell migration-promoting effect. In this study, the therapy with HGF-pretreated hADSCs was expected to enhance the therapeutic effect in the amelioration of liver fibrosis compared with untreated hADSCs.   Method: HGF-hADSCs were prepared by culturing hADSCs for seven days in the medium added HGF. HGF-hADSCs transplantation was performed to investigate the therapeutic effect of these cells on carbon tetrachloride (CCl4)-induced liver fibrosis in a mouse model.  Results: After seven days and fourteen days of cell transfusion, HGF-hADSCs ameliorated the liver fibrosis. The results showed the attenuation of the liver injury (ALT level), the down-regulation of procollagen-1 (7 days, 3-fold; 14 days, 6.7-fold) and alpha -smooth muscle actin (alpha-SMA) expression (7 days, 10-fold; 14 days, 2-fold), and the histological improvement. Notably, there was the significant difference in the procollagen-1 between HGF-hADSCs and untreated hADSCs groups. Thus, the therapy with HGF-hADSCs was more efficient in the liver fibrosis treatment compared with untreated hADSCs.  Conclusion: HGF pretreated hADSCs have a potential therapy in the treatment of liver fibrosis

Sign in / Sign up

Export Citation Format

Share Document